Featured Articles

  1. Answer Your Critical Clinical Questions — Faster Than Ever 2/19/2025

    Pressing clinical planning questions to ask about feasibility, investigator selection, patient enrollment, clinical trial disclosure, and more.

  2. Antibody-Drug Conjugates: 'Magic Bullets' Become Reality 2/19/2025

    Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including antibody-drug conjugates (ADCs). Learn more about ADCs’ makeup, mechanisms, and the development landscape.

  3. The Scoop On The SCOPE Summit 2/19/2025

    From industry partnerships to patient recruitment to proprietary data, SCOPE 2025 was packed with informational sessions.

  4. Merits Of A Multifaceted Approach To Clinical Trial Recruitment 1/27/2025

    The best way to address clinical trial recruitment challenges is with a multifaceted approach that goes beyond traditional channels and ways of thinking.

  5. Use Case: A Patient-Centric Approach To Site Selection 1/27/2025

    Discover how Citeline’s robust datasets, combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease. 

  6. What's The Current & Future Impact Of AI On Pharmaceutical R&D 1/17/2025

    Explore the results of a survey where senior decision-makers in the life sciences industry provided their perceptions and expectations of AI to understand current AI adoption trends.

  7. What Does 2025 Hold For Pharma? 1/17/2025

    Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

  8. Top 10 Tips For Diversity Plans 12/13/2024

    Explore the updated guidance from the FDA to enhance diversity in clinical trials, including ten times to developing a comprehensive Diversity Action Plans.

  9. Artificial Intelligence Regulation 12/13/2024

    To make the best use of artificial intelligence (AI), drug sponsors need to understand where health authorities are drawing the lines.

  10. Ensuring A Diverse Patient Population In Clinical Trials 12/13/2024

    In 2025, the FDA will require pharmaceutical companies to include diversity action plans (DAPs) for Phase II and pivotal studies.